14th European Congress of Clinical Microbiology and Infectious ...

Poster Sessions Monday, May 3, 2004
P1146 Results of multicentre study of antimicrobial
resistance of nasopharyngeal Streptococcus
pneumoniae in children from day-care centres
and orphanages in Asian Russia
(SPARS-ASIA study)
R.S. Kozlov, P.C. Appelbaum, K. Kosowska,
O.I. Kretchikova, L.S. Stratchounski
(Smolensk, RUS; Hershey, USA)
P1147 Antimicrobial susceptibility of Streptococcus
pneumoniae isolated from adults with acute
sinusitis in three Russian centres
L. Stratchounski, A. Tarasov, R. Kozlov, I. Edelstein,
A. Kryukov, T. Alexanyan, A. Sedinkin, J. Yanov,
D. Sergeev, O. Kretchikova, M. Sukhorukova
(Smolensk, Moscow, St. Petersburg, RUS)
P1148 Distribution of macrolide resistance
mechanisms in Streptococcus pneumoniae:
3-year update from the PROTEKT study
D. Farrell, I. Morrissey
The PROTEKT Study Group
P1149 Susceptibility of Streptococcus pneumoniae
to penicillin, azithromycin and telithromycin
(PROTEKT 1999–2002)
G. Schito, D. Felmingham
The PROTEKT Study Group
P1150 Serotype distribution and antimicrobial
resistance of Streptococcus pneumoniae in
Austria, 1996–2002: Implications for
vaccination strategies
A. Buxbaum, S. Forsthuber, W. Graninger,
A. Georgopoulos – Austrian Bacterial Surveillance
Network
P1151 Tracking the activity of levofloxacin and
comparator compounds against Streptococcus
pneumoniae collected from five European
countries during 2001–2002 and 2003
R. Blosser, J. Karlowsky, D. Sahm, M. Jones
(Herndon, USA)
P1152 Antibiotic sensitivity and serotypes of
S. pneumoniae isolates in blood culture
during a 12-year period in a community-based
hospital in Madrid, Spain
M.D. Martín-Rodrigo, G. Seseña,
S.M. Quevedo-Soriano, R. Jimenez, Y. Gil,
J.M. del Álamo, A.C. Velasco, I. Wilhelmi
(Leganés, E)
P1153 Antimicrobial resistance among communityacquired
respiratory tract infections in Brazil:
PROTEKT 2002
C. Mendes, C. Kiffer, J. Sampaio, C. Oplustil,
C. Zoccoli, C. Dias, D. Farrell, D. Felmingham –
PROTEKT Brazil Group
P1154 Study of invasive penicillin-resistant
pneumococci isolated in Romania between
2000–2003
M. Pana, M. Ghita, S. Iacob, O. Dorobat,
R. Papagheorghe, N. Popescu, G. Bancescu,
M. Andrei, V. Ungureanu, I. Nistor, S. Botea
(Bucharest, RO)
P1155 Analysis of macrolide-resistant isolates of
Streptococcus pneumoniae gained from the
Far East of Russia
A. Martynova, V. Turcutyuikov (Vladivostok, RUS)
P1156 Impact of telithromycin versus azithromycin
on the nasopharyngeal microflora of patients
with respiratory tract infections caused by
pneumococci
J.P. Guggenbichler, G. Juhl, R.B. Nieman,
E. Wahlund, C.E. Nord (Erlangen, Munich, D;
Bridgewater, USA; Stockholm, S)
13:00–14:00
Antibiotic therapy and public health issues
P1157 Process costs of intravenous antibiotic
therapy for community-acquired intraabdominal
infections
R. Andersson, G. Eckerwall, M. Nuijten,
P. Engelfriet, S. Sen
(Lund, S; Jisp, NL; Whitehouse Station, USA)
P1158 Economic impact of S. pneumoniae macrolide
resistance in children with acute otitis media
in five European countries
M. Sikirica, R. Mera, M. Higashi, J. Davidson
(Collegeville, USA; Greenford, UK)
P1159 Comparison of level of physician satisfaction
with ertapenem, piperacillin/tazobactam and
Cceftriaxone/metronidazole for the treatment
of community-acquired intra-abdominal
infections requiring surgery
A. De La Pena, N. Navarro, W. Asperger,
P. Mavros, C. Chan, M. Shivaprakash, S. Sen –
OASIS Study Team
P1160 Fixed-dose combination drugs for
tuberculosis and HIV/AIDS:
what are the issues?
J. Primo-Carpenter (Rockville, USA)
www.escmid.org/eccmid2004
page 105